Zachary Hartman
Overview:
My research interests encompass studies of immunity and inflammation in the context of developing and established cancers. These research interests involve studies of inflammation in the genesis and maintenance of specific cancer types (principally breast and ovarian), as well as the impact of inflammation on tumor metastasis and the tumor microenvironment. My group is also involved in strategies to modulate the immune response to tumors, which involves the use of novel immunotherapeutic strategies and development of vaccines to specific oncogenic targets. The major focus of my lab is in uncovering strategies to modulate tumor-derived inflammation and tumor-specific immunity that will translate into clinically efficacious therapies in patients.
Positions:
Associate Professor in Surgery
Surgery, Surgical Sciences
School of Medicine
Assistant Professor in Immunology
Integrative Immunobiology
School of Medicine
Associate Professor in Pathology
Pathology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
Ph.D. 2006
Duke University
Postdoctoral Fellow
Duke University
Postdoctoral Fellow, Md Anderson Cancer Center
University of Texas Medical School, Houston
Grants:
A Neoepitope Subunit Vaccine Targeting the Mutated Estrogen Receptor Ligand Binding Domain to Treat and Prevent Endocrine Resistant ER+ Breast Cancer
Administered By
Surgery, Surgical Sciences
Awarded By
Department of Defense
Role
Principal Investigator
Start Date
End Date
Study of LAMP Vaccines in HER2+ Breast Cancer
Administered By
Surgery, Surgical Sciences
Awarded By
Immunomic Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date
Investigation of stimulating stress response mechanisms to enhance antibody dependent cellular phagocytosis
Administered By
Surgery, Surgical Sciences
Awarded By
Bantam Pharmaceutical, LLC
Role
Principal Investigator
Start Date
End Date
Investigating the adaptive immune response to dormant tumor cells
Administered By
Surgery, Surgical Sciences
Awarded By
American Cancer Society, Inc.
Role
Principal Investigator
Start Date
End Date
Investigation of LAMP anti-tumor vaccines
Administered By
Surgery, Surgical Sciences
Awarded By
Immunomic Therapeutics, Inc.
Role
Principal Investigator
Start Date
End Date
Publications:
Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase
<jats:p><p>d16HER2 mammary intraepithelial neoplasm. d16HER2 shown in magenta. Krt14 antibody staining shown in green.</p></jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
MLA Citation
Ginzel, Joshua D., et al. Movie 5 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22526405.v1.
URI
https://scholars.duke.edu/individual/pub1571963
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526405.v1
Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase
<jats:p><p>p95HER2 invasive carcinoma. p95HER2 shown in magenta. Krt14 antibody staining shown in green.</p></jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
MLA Citation
Ginzel, Joshua D., et al. Movie 3 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22526414.v1.
URI
https://scholars.duke.edu/individual/pub1571979
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526414.v1
Figure S4 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
<jats:p><p>Individual histograms of perforin expression by memory CD8 T cell cluster pre- and post-vaccination</p></jats:p>
Authors
Crosby, EJ; Gwin, W; Blackwell, K; Marcom, PK; Chang, S; Maecker, HT; Broadwater, G; Hyslop, T; Kim, S; Rogatko, A; Lubkov, V; Snyder, JC; Osada, T; Hobeika, AC; Morse, MA; Lyerly, HK; Hartman, ZC
MLA Citation
Crosby, Erika J., et al. Figure S4 from Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. 31 Mar. 2023. Crossref, doi:10.1158/1078-0432.22472853.
URI
https://scholars.duke.edu/individual/pub1571737
Source
crossref
Published Date
DOI
10.1158/1078-0432.22472853
Supplementary Figure 7 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase
<jats:p><p>mRNA FISH of cell state markers</p></jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
MLA Citation
Ginzel, Joshua D., et al. Supplementary Figure 7 from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22526384.
URI
https://scholars.duke.edu/individual/pub1571964
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526384
Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase
<jats:p><p>Supplementary Table 1: Cluster-specific markers from all cells (8,486 cells) Supplementary Table 2: Cluster-specific markers from all epithelial cells (3,843 cells) Supplementary Table 3: Cluster-specific markers from all immune cells (1,803 cells) Supplementary Table 4: Cluster-specific markers from all fibroblast cells (922 cells) Supplementary Table 5a: State-specific markers from all d16:HBOW epithelial cells (1,421 cells) Supplementary Table 5b: State-specific markers from all p95:HBOW epithelial cells (1,258 cells)</p></jats:p>
Authors
Ginzel, JD; Acharya, CR; Lubkov, V; Mori, H; Boone, PG; Rochelle, LK; Roberts, WL; Everitt, JI; Hartman, ZC; Crosby, EJ; Barak, LS; Caron, MG; Chen, JQ; Hubbard, NE; Cardiff, RD; Borowsky, AD; Lyerly, HK; Snyder, JC
MLA Citation
Ginzel, Joshua D., et al. Supplementary Tables 1-5 for scRNAseq marker genes from HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase. 3 Apr. 2023. Crossref, doi:10.1158/1541-7786.22526378.v1.
URI
https://scholars.duke.edu/individual/pub1571980
Source
crossref
Published Date
DOI
10.1158/1541-7786.22526378.v1
Associate Professor in Surgery
Contact:
Box 2606 Med Ctr, Durham, NC 27710
Research Drive, Msrbi Rm 414, Durham, NC 27710